Preclinical Data From Amgen's Oncology Pipeline to be Present... ( Early Research Suggests that Understa...)

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

Date:4/16/2009

Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF - A

Amgen Launches Angiogenesis Website

THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22, 2009.

Data will be presented on investigational compounds AMG 386, a peptibody that binds to and inhibits angiopoietins 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth factor receptor (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met receptor.

"The data being presented at this meeting further our biologic understanding of these novel compounds and pathways, and inform our thinking regarding opportunities to develop predictive or prognostic biomarkers," said C. Glenn Begley, M.D., vice president, Global Hematology and Oncology Research at Amgen. "This is an exciting year for our oncology therapeutics pipeline, as results from a number of clinical programs become available."

Selected Abstracts of Interest
-- Assessment of angiogenesis inhibitors in the retinopathy of
prematurity model in mice
Overview: Examined the inhibition of the VEGF/VEGFR pathway with AMG
273 and the inhibition of the angiopoietin/Tie2 pathway with AMG 386
Lead author: Estrada J.
Abstract No. 140 (Sunday, April 19, 2009, 8:00 am - 12:00 pm)

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies

Post Your Comments:

Preclinical Data From Amgen's Oncology Pipeline to be Present...( Early Research Suggests that Understa...)